Cargando…

1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents

A new series of twenty-three 1,5-benzodiazepin-2(3H)-ones were synthesized and evaluated in the 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS), ferric reducing antioxidant power (FRAP), and 2,2-diphenyl-1-picrylhydrazyl (DPPH) assays as a new chemotype with antioxidant and good drug-li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ortíz de Zárate, Ana, Pérez-Torralba, Marta, Bonet Isidro, Iñigo, López, Concepción, Claramunt, Rosa M., Martínez-Casanova, Diana, Sánchez-Vera, Isabel, Jiménez-González, Jesús, Lavandera, José Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533176/ https://www.ncbi.nlm.nih.gov/pubmed/34679721 http://dx.doi.org/10.3390/antiox10101584

Ejemplares similares

Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems
por: Paccione, Nicola, et al.
Publicado: (2022)

Antipsychotics dosage and antiparkinsonian prescriptions
por: Acquaviva, Eric, et al.
Publicado: (2007)

Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs
por: Silva, Sara, et al.
Publicado: (2021)

A STUDY OF PROPHYLACTIC VALUE OF ANTIPARKINSONIAN DRUG
por: Behere, P.B., et al.
Publicado: (1983)

Coumarin analogue 3-methyl-7H-furo[3,2-g]chromen-7-one as a possible antiparkinsonian agent
por: Olaya, María del Pilar, et al.
Publicado: (2019)

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder
por: Massari, Caio M., et al.
Publicado: (2017)

Trends in Antiparkinsonian Medication Use in New Zealand: 1995–2011
por: Pitcher, T. L., et al.
Publicado: (2014)

Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication
por: Chung, Jae Woo, et al.
Publicado: (2017)

Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets
por: Michel, Anne, et al.
Publicado: (2017)

Structure of 1,5-benzodiazepinones in the solid state and in solution: Effect of the fluorination in the six-membered ring
por: Pérez-Torralba, Marta, et al.
Publicado: (2013)

The Antiparkinsonian and Antidyskinetic Mechanisms of Mucuna pruriens in the MPTP-Treated Nonhuman Primate
por: Lieu, Christopher A., et al.
Publicado: (2012)

Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson’s disease
por: Taguchi, Soutarou, et al.
Publicado: (2021)

Orthostatic Hypotension and Antiparkinsonian Drugs: A Systematic Review and Meta-analysis
por: Nimmons, Danielle, et al.
Publicado: (2021)

Antiparkinsonian medication masks motor signal progression in de novo patients()
por: Brzezicki, Maksymilian A., et al.
Publicado: (2023)

Deciphering the Actions of Antiparkinsonian and Antipsychotic Drugs on cAMP/DARPP-32 Signaling
por: Bonito-Oliva, Alessandra, et al.
Publicado: (2011)

Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications
por: Miguelez, Cristina, et al.
Publicado: (2017)

Predictive Factors of Antiparkinsonian Drug Reduction after Subthalamic Stimulation for Parkinson’s Disease
por: SAMURA, Kazuhiro, et al.
Publicado: (2019)

Time until modification of antiparkinsonian therapy in a group of patients from Colombia
por: Valencia-Vásquez, Aníbal, et al.
Publicado: (2023)

Evaluation of the Antioxidant and Neuroprotectant Activities of New Asymmetrical 1,3-Diketones
por: Nieto, Carla I., et al.
Publicado: (2018)

4-Phenyl-1H-1,5-benzodiazepin-2(3H)-one
por: Akkurt, Mehmet, et al.
Publicado: (2012)

Synthesis and Pharmacological Valorization of Derivatives of 4-Phenyl-1,5-Benzodiazepin-2-One
por: Nguema Ongone, Terence, et al.
Publicado: (2018)

A New Stereoselective Approach to the Substitution of Allyl Hydroxy Group in para-Mentha-1,2-diol in the Search for New Antiparkinsonian Agents
por: Podturkina, Alexandra V., et al.
Publicado: (2023)

Rapid preparation process of antiparkinsonian drug Mucuna pruriens silver nanoparticle by bioreduction and their characterization
por: Arulkumar, Subramanian, et al.
Publicado: (2010)

c-Abl Inhibition Exerts Symptomatic Antiparkinsonian Effects Through a Striatal Postsynaptic Mechanism
por: Zhou, Yu, et al.
Publicado: (2018)

LUHMES Cells: Phenotype Refinement and Development of an MPP(+)-Based Test System for Screening Antiparkinsonian Drugs
por: Beliakov, Sergei V., et al.
Publicado: (2023)

4-Methyl-2,3-dihydro-1H-1,5-benzodiazepin-2-one monohydrate
por: Saber, Asmaa, et al.
Publicado: (2010)

Motor Improvement-Related Regional Cerebral Blood Flow Changes in Parkinson's Disease in Response to Antiparkinsonian Drugs
por: Taguchi, Soutarou, et al.
Publicado: (2019)

Regioselective One-Pot Synthesis, Biological Activity and Molecular Docking Studies of Novel Conjugates N-(p-Aryltriazolyl)-1,5-benzodiazepin-2-ones as Potent Antibacterial and Antifungal Agents
por: Nsira, Asma, et al.
Publicado: (2022)

1-Allyl-4-phenyl-2,3-dihydro-1H-1,5-benzodiazepin-2-one
por: Ballo, Daouda, et al.
Publicado: (2010)

The 5-HT(2A) Receptor Antagonist M100907 Produces Antiparkinsonian Effects and Decreases Striatal Glutamate
por: Ansah, Twum A., et al.
Publicado: (2011)

Regiospecific Synthesis and Structural Studies of 3,5-Dihydro-4H-pyrido[2,3-b][1,4]diazepin-4-ones and Comparison with 1,3-Dihydro-2H-benzo[b][1,4]diazepin-2-ones
por: Núñez Alonso, David, et al.
Publicado: (2020)

3-Allyl-1,5-dibenzyl-1,5-benzodiazepine-2,4-dione
por: Jabli, Hind, et al.
Publicado: (2009)

The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database
por: Johannes, Catherine B., et al.
Publicado: (2022)

Crystal structure and Hirshfeld surface analysis of a new benzodiazepine derivative: 4-dichloromethyl-2,3-dihydro-1H-1,5-benzodiazepin-2-one
por: Chkirate, Karim, et al.
Publicado: (2019)

From benzodiazepine to pregabalin dependence: Different agents, similar problems
por: Gahr, Maximilian, et al.
Publicado: (2015)

1,5-Dibenzyl-3-propargyl-1,5-benzodiazepine-2,4-dione
por: Jabli, Hind, et al.
Publicado: (2009)

Blockade of fast A-type and TEA-sensitive potassium channels provide an antiparkinsonian effect in a 6-OHDA animal model
por: Haghdoost-Yazdi, Hashem, et al.
Publicado: (2017)

Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABA(A) receptor subtype
por: Ralvenius, William T., et al.
Publicado: (2015)

Remimazolam – current knowledge on a new intravenous benzodiazepine anesthetic agent
por: Kim, Seong-Hyop, et al.
Publicado: (2022)

4-Phenyl-1-(prop-2-yn-1-yl)-1H-1,5-benzodiazepin-2(3H)-one
por: Loughzail, Mohamed, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_p9dkurbh20r479knmtjp8u8hjj